GERATHERM MEDICAL AG (GME.DE) Fundamental Analysis & Valuation

FRA:GME • DE0005495626

Current stock price

2.8 EUR
+0.1 (+3.7%)
Last:

This GME.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. GME.DE Profitability Analysis

1.1 Basic Checks

  • GME had positive earnings in the past year.
  • In the past year GME had a positive cash flow from operations.
  • Each year in the past 5 years GME has been profitable.
  • GME had a positive operating cash flow in each of the past 5 years.
GME.DE Yearly Net Income VS EBIT VS OCF VS FCFGME.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M

1.2 Ratios

  • GME's Return On Assets of 2.56% is in line compared to the rest of the industry. GME outperforms 41.94% of its industry peers.
  • GME has a Return On Equity of 3.39%. This is comparable to the rest of the industry: GME outperforms 40.32% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 4.77%, GME is in line with its industry, outperforming 40.32% of the companies in the same industry.
  • GME had an Average Return On Invested Capital over the past 3 years of 5.40%. This is below the industry average of 10.01%.
Industry RankSector Rank
ROA 2.56%
ROE 3.39%
ROIC 4.77%
ROA(3y)2.74%
ROA(5y)2.85%
ROE(3y)4.3%
ROE(5y)4.73%
ROIC(3y)5.4%
ROIC(5y)5.44%
GME.DE Yearly ROA, ROE, ROICGME.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2 4 6 8 10

1.3 Margins

  • GME has a Profit Margin (5.04%) which is in line with its industry peers.
  • GME's Profit Margin has improved in the last couple of years.
  • GME has a Operating Margin (10.70%) which is comparable to the rest of the industry.
  • In the last couple of years the Operating Margin of GME has grown nicely.
  • GME has a worse Gross Margin (45.35%) than 74.19% of its industry peers.
  • GME's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 10.7%
PM (TTM) 5.04%
GM 45.35%
OM growth 3Y34.1%
OM growth 5Y23.14%
PM growth 3Y114.71%
PM growth 5Y12.9%
GM growth 3Y-12.69%
GM growth 5Y-8.03%
GME.DE Yearly Profit, Operating, Gross MarginsGME.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. GME.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so GME is destroying value.
  • The number of shares outstanding for GME remains at a similar level compared to 1 year ago.
  • GME has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for GME has been reduced compared to a year ago.
GME.DE Yearly Shares OutstandingGME.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
GME.DE Yearly Total Debt VS Total AssetsGME.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • GME has an Altman-Z score of 2.58. This is not the best score and indicates that GME is in the grey zone with still only limited risk for bankruptcy at the moment.
  • GME has a Altman-Z score of 2.58. This is comparable to the rest of the industry: GME outperforms 53.23% of its industry peers.
  • There is no outstanding debt for GME. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 1.27
Altman-Z 2.58
ROIC/WACC0.81
WACC5.9%
GME.DE Yearly LT Debt VS Equity VS FCFGME.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M 15M 20M

2.3 Liquidity

  • A Current Ratio of 3.04 indicates that GME has no problem at all paying its short term obligations.
  • The Current ratio of GME (3.04) is better than 80.65% of its industry peers.
  • A Quick Ratio of 2.35 indicates that GME has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 2.35, GME belongs to the best of the industry, outperforming 85.48% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.04
Quick Ratio 2.35
GME.DE Yearly Current Assets VS Current LiabilitesGME.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. GME.DE Growth Analysis

3.1 Past

  • GME shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -37.95%.
  • Measured over the past 5 years, GME shows a small growth in Earnings Per Share. The EPS has been growing by 3.45% on average per year.
  • Looking at the last year, GME shows a very negative growth in Revenue. The Revenue has decreased by -33.29% in the last year.
  • GME shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -6.77% yearly.
EPS 1Y (TTM)-37.95%
EPS 3Y86.77%
EPS 5Y3.45%
EPS Q2Q%84.62%
Revenue 1Y (TTM)-33.29%
Revenue growth 3Y-16.42%
Revenue growth 5Y-6.77%
Sales Q2Q%-3.99%

3.2 Future

  • GME is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.06% yearly.
  • Based on estimates for the next years, GME will show a decrease in Revenue. The Revenue will decrease by -0.56% on average per year.
EPS Next Y-80%
EPS Next 2Y9.54%
EPS Next 3Y30.06%
EPS Next 5YN/A
Revenue Next Year-12.36%
Revenue Next 2Y-3.72%
Revenue Next 3Y-0.56%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
GME.DE Yearly Revenue VS EstimatesGME.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 5M 10M 15M 20M 25M
GME.DE Yearly EPS VS EstimatesGME.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2022 2023 2024 2025 2026 2027 0.2 0.4 0.6

More info and screens

Find the best growth stocksShow best growing peers

4

4. GME.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 21.54 indicates a rather expensive valuation of GME.
  • Based on the Price/Earnings ratio, GME is valued a bit cheaper than the industry average as 72.58% of the companies are valued more expensively.
  • GME is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 24.88, which is the current average of the S&P500 Index.
  • With a Price/Forward Earnings ratio of 46.20, GME can be considered very expensive at the moment.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of GME indicates a slightly more expensive valuation: GME is more expensive than 67.74% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 22.19. GME is valued rather expensively when compared to this.
Industry RankSector Rank
PE 21.54
Fwd PE 46.2
GME.DE Price Earnings VS Forward Price EarningsGME.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • GME's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. GME is cheaper than 100.00% of the companies in the same industry.
  • GME's Price/Free Cash Flow ratio is rather cheap when compared to the industry. GME is cheaper than 98.39% of the companies in the same industry.
Industry RankSector Rank
P/FCF 7.36
EV/EBITDA 2.07
GME.DE Per share dataGME.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3

4.3 Compensation for Growth

  • A more expensive valuation may be justified as GME's earnings are expected to grow with 30.06% in the coming years.
PEG (NY)N/A
PEG (5Y)6.25
EPS Next 2Y9.54%
EPS Next 3Y30.06%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. GME.DE Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 3.57%, GME has a reasonable but not impressive dividend return.
  • Compared to an average industry Dividend Yield of 1.21, GME pays a better dividend. On top of this GME pays more dividend than 93.55% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.89, GME pays a better dividend.
Industry RankSector Rank
Dividend Yield 3.57%

5.2 History

  • The dividend of GME decreases each year by -24.21%.
Dividend Growth(5Y)-24.21%
Div Incr Years0
Div Non Decr Years0
GME.DE Yearly Dividends per shareGME.DE Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 0 0 0 0 0

5.3 Sustainability

  • 76.72% of the earnings are spent on dividend by GME. This is not a sustainable payout ratio.
DP76.72%
EPS Next 2Y9.54%
EPS Next 3Y30.06%
GME.DE Yearly Income VS Free CF VS DividendGME.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1M -1M 2M -2M
GME.DE Dividend Payout.GME.DE Dividend Payout, showing the Payout Ratio.GME.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

GME.DE Fundamentals: All Metrics, Ratios and Statistics

GERATHERM MEDICAL AG

FRA:GME (3/25/2026, 7:00:00 PM)

2.8

+0.1 (+3.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A
Earnings (Next)06-02
Inst Owners0.14%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap15.15M
Revenue(TTM)13.98M
Net Income(TTM)705.20K
Analysts80
Price Target6.12 (118.57%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.57%
Yearly Dividend0.1
Dividend Growth(5Y)-24.21%
DP76.72%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)200%
EPS NY rev (3m)200%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 21.54
Fwd PE 46.2
P/S 1.08
P/FCF 7.36
P/OCF 6.33
P/B 0.73
P/tB 0.79
EV/EBITDA 2.07
EPS(TTM)0.13
EY4.64%
EPS(NY)0.06
Fwd EY2.16%
FCF(TTM)0.38
FCFY13.58%
OCF(TTM)0.44
OCFY15.8%
SpS2.58
BVpS3.85
TBVpS3.54
PEG (NY)N/A
PEG (5Y)6.25
Graham Number3.36
Profitability
Industry RankSector Rank
ROA 2.56%
ROE 3.39%
ROCE 6.9%
ROIC 4.77%
ROICexc 8.56%
ROICexgc 9.92%
OM 10.7%
PM (TTM) 5.04%
GM 45.35%
FCFM 14.71%
ROA(3y)2.74%
ROA(5y)2.85%
ROE(3y)4.3%
ROE(5y)4.73%
ROIC(3y)5.4%
ROIC(5y)5.44%
ROICexc(3y)7.14%
ROICexc(5y)8.66%
ROICexgc(3y)8.81%
ROICexgc(5y)10.98%
ROCE(3y)7.81%
ROCE(5y)7.88%
ROICexgc growth 3Y2.27%
ROICexgc growth 5Y6.75%
ROICexc growth 3Y7.82%
ROICexc growth 5Y8.18%
OM growth 3Y34.1%
OM growth 5Y23.14%
PM growth 3Y114.71%
PM growth 5Y12.9%
GM growth 3Y-12.69%
GM growth 5Y-8.03%
F-Score4
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 1.27
Debt/EBITDA 0
Cap/Depr 22.42%
Cap/Sales 2.41%
Interest Coverage 20.21
Cash Conversion 79.84%
Profit Quality 291.69%
Current Ratio 3.04
Quick Ratio 2.35
Altman-Z 2.58
F-Score4
WACC5.9%
ROIC/WACC0.81
Cap/Depr(3y)105.18%
Cap/Depr(5y)120.77%
Cap/Sales(3y)7.67%
Cap/Sales(5y)7.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-37.95%
EPS 3Y86.77%
EPS 5Y3.45%
EPS Q2Q%84.62%
EPS Next Y-80%
EPS Next 2Y9.54%
EPS Next 3Y30.06%
EPS Next 5YN/A
Revenue 1Y (TTM)-33.29%
Revenue growth 3Y-16.42%
Revenue growth 5Y-6.77%
Sales Q2Q%-3.99%
Revenue Next Year-12.36%
Revenue Next 2Y-3.72%
Revenue Next 3Y-0.56%
Revenue Next 5YN/A
EBIT growth 1Y-44.18%
EBIT growth 3Y12.09%
EBIT growth 5Y14.8%
EBIT Next Year300%
EBIT Next 3Y71%
EBIT Next 5Y42.35%
FCF growth 1Y112.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-0.95%
OCF growth 3Y16.98%
OCF growth 5Y-0.95%

GERATHERM MEDICAL AG / GME.DE Fundamental Analysis FAQ

What is the fundamental rating for GME stock?

ChartMill assigns a fundamental rating of 5 / 10 to GME.DE.


Can you provide the valuation status for GERATHERM MEDICAL AG?

ChartMill assigns a valuation rating of 4 / 10 to GERATHERM MEDICAL AG (GME.DE). This can be considered as Fairly Valued.


What is the profitability of GME stock?

GERATHERM MEDICAL AG (GME.DE) has a profitability rating of 4 / 10.


Can you provide the financial health for GME stock?

The financial health rating of GERATHERM MEDICAL AG (GME.DE) is 8 / 10.


What is the expected EPS growth for GERATHERM MEDICAL AG (GME.DE) stock?

The Earnings per Share (EPS) of GERATHERM MEDICAL AG (GME.DE) is expected to decline by -80% in the next year.